Oncology

News

Genmab offers $1.8bn for ADC specialist ProfoundBio

Antibody developer Genmab has made a play to boost its expertise in the scalding hot area of antibody-drug conjugates (ADCs), agreeing a $1.8 billion deal to acquire Profo

R&D

R&D in 2023 sees focus return to oncology

After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms.

News

AZ, Daiichi Sankyo file Dato-DXd for second indication

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (

News

Ipsen licenses Sutro ADC in $900m deal

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

News

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment

News

Nuvation Bio nears commercial stage with AnHeart buy

Nuvation Bio has accelerated its development into a commercial-stage biotech with a deal to acquire AnHeart Therapeutics and its late-stage lung cancer therapy taletrectin

Genmab offers $1.8bn for ADC specialist ProfoundBio

R&D in 2023 sees focus return to oncology

AZ, Daiichi Sankyo file Dato-DXd for second indication

Ipsen licenses Sutro ADC in $900m deal

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Nuvation Bio nears commercial stage with AnHeart buy

Australia starts probe into AI infiltration of Medicare

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks